Q1 2025 Management View CEO John Marchioni highlighted a combined ratio of 96.1% for the quarter and net premiums written ...

The Risk Estimation of Tumor REcurrence After Transplant score accurately predicted hepatocellular carcinoma recurrence after liver transplantation.

Preferred shares offer lower risk and high yields; recent trades in DX-C and EFC-B have been profitable. Click here for more ...